ClinicalTrials.gg
CompletedNCT03363854Updated Mar 11, 2025Results posted

Tralokinumab in Combination With Topical Corticosteroids for Moderate to Severe Atopic Dermatitis - ECZTRA 3

A Phase 3 interventional study of Tralokinumab and Placebo in Atopic Dermatitis, sponsored by LEO Pharma. Completed at 66 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-03-11.

Sponsored by LEO Pharma · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
380
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 16 studies testing tralokinumab in Dermatitis, Atopic — 2 open to participants now, 2 under way, 1 of them phase 3. tralokinumab · Dermatitis, Atopic.

Enrollment
4th of 16
380 · median 205
Started
2018
with 5 others
Phase 3
10 of 16
1 open now
Registered
3rd of 16
by date
Lead sponsor
13 of 16
LEO Pharma

Among the 16 studies testing tralokinumab in Dermatitis, Atopic, this one is the 4th largest by enrollment, is one of 6 that started in 2018, is one of 10 in phase 3, and was the 3rd registered.

Dermatitis, Atopic

1,596 studies on the registry are indexed under Dermatitis, Atopic; 289 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

2 of the 16 studies testing tralokinumab in Dermatitis, Atopic are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About tralokinumab

tralokinumab: first FDA approval 2021 (ADBRY), first EMA approval 2021. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 195 Dermatitis, Atopic studies recruiting now, 84 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 52 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies testing tralokinumab in Dermatitis, Atopic, or all of them as a file.
02

Study summary

Primary objective:

To demonstrate that tralokinumab in combination with topical corticosteroids (TCS) is superior to placebo in combination with TCS in treating moderate-to-severe atopic dermatitis (AD).

Secondary objectives:

To evaluate the efficacy of tralokinumab in combination with TCS on severity and extent of AD, itch, and health-related quality of life compared with placebo in combination with TCS.

To assess the safety of tralokinumab in combination with TCS when used to treat moderate-to-severe AD for 32 weeks.

03

Conditions studied

  • Atopic Dermatitis

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 and above.
  • Diagnosis of AD as defined by the Hanifin and Rajka (1980) criteria for AD.
  • History of AD for ≥1 year.
  • Subjects who have a recent history of inadequate response to treatment with topical medications.
  • AD involvement of ≥10% body surface area at screening and baseline.
  • Stable dose of emollient twice daily (or more, as needed) for at least 14 days before randomisation.

Exclusion criteria

Exclusion Criteria:

  • Subjects for whom TCS are medically inadvisable e.g., due to important side effects or safety risks in the opinion of the investigator.
  • Active dermatologic conditions that may confound the diagnosis of AD.
  • Use of tanning beds or phototherapy within 6 weeks prior to randomisation.
  • Treatment with systemic /immunomodulating drugs and/or systemic within 4 weeks prior to randomisation.
  • Treatment with TCS, topical calcineurin inhibitors (TCI), or topical phosphodiesterase 4 (PDE-4) inhibitor within 2 weeks prior to randomisation.
  • Receipt of any marketed biological therapy (i.e. immunoglobulin, anti- immunoglobulin E) including dupilumab or biologic agents within 3 months or 5 half-lives, whichever is longer prior to randomisation.
  • Active skin infection within 1 week prior to randomisation.
  • infection within 4 weeks prior to randomisation.
  • A helminth parasitic infection within 6 months prior to the date is obtained.
  • Tuberculosis requiring treatment within the 12 months prior to screening.
  • Known primary immunodeficiency disorder.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
380 participants (actual)

Study arms

  • Experimental
    Tralokinumab(initial)responders-> Tralokinumab(continuation A)

    Week 0 to 16 (initial period): Tralokinumab loading SC injection on Day 0 followed by tralokinumab injection regimen A. Week 16 to 32 (continuation period): Tralokinumab continuation SC injection regimen A.

    Drug: Tralokinumab

  • Experimental
    Tralokinumab(initial)responders-> Tralokinumab(continuation B)

    Week 0 to 16 (initial period): Tralokinumab loading SC injection on Day 0 followed by tralokinumab injection regimen A. Week 16 to 32 (continuation period): Tralokinumab continuation SC injection regimen B.

    Drug: Tralokinumab

  • Experimental
    Tralokinumab(initial)non-respon-> Tralokinumab(continuation A)

    Week 0 to 16 (initial period): Tralokinumab loading SC injection on Day 0 followed by tralokinumab injection regimen A. Week 16 to 32 (continuation period): Tralokinumab continuation SC injection regimen A.

    Drug: Tralokinumab

  • Experimental
    Placebo (initial)non-respon-> Tralokinumab(continuation A)

    Week 0 to 16 (initial period): Placebo loading SC injection on Day 0 followed by placebo injection regimen A. Week 16 to 32 (continuation period): Tralokinumab continuation SC injection regimen A.

    Drug: Tralokinumab · Drug: Placebo

  • Placebo comparator
    Placebo(initial)responders-> Placebo(continuation A)

    Week 0 to 16 (initial period): Placebo loading SC injection on Day 0 followed by placebo injection regimen A. Week 16 to 32 (continuation period): Placebo continuation SC injection regimen A.

    Drug: Placebo

Interventions

  • Tralokinumab is a human recombinant monoclonal antibody of the IgG4 subclass that specifically binds to human IL-13 and blocks interaction with the IL-13 receptors. It is presented as a liquid formulation for subcutaneous (SC) administration.

  • DrugPlacebo

    Placebo contains the same excipients in the same concentration only lacking tralokinumab.

06

What researchers measure

Primary outcomes

  1. Participants With Investigator's Global Assessment (IGA) Score of 0 (Clear) or 1 (Almost Clear) at Week 16

    IGA is used to evaluate the severity of atopic dermatitis. It is a 5-point score ranging from 0 (clear) to 4 (severe).

    Time frame: Week 16

  2. Participants Achieving at Least 75% Reduction in Eczema Area and Severity Index (EASI) at Week 16

    EASI is used to evaluate the extent and severity of atopic dermatitis. It is a composite score ranging from 0 to 72 with a higher score indicating a more extensive and/or severe condition.

    Time frame: Week 16

Secondary outcomes

  1. Reduction of Worst Daily Pruritus Numeric Rating Scale (NRS) (Weekly Average) of at Least 4 From Baseline to Week 16

    Worst Daily Pruritus NRS is used by the participant to evaluate their worst itch severity over the past 24 hours. The score ranges from 0 ('no itch') to 10 ('worst itch imaginable') on an 11-point scale.

    Time frame: Week 0 to Week 16

  2. Change in Scoring Atopic Dermatitis (SCORAD) From Baseline to Week 16

    SCORAD is used to evaluate the extent and severity of atopic dermatitis as well as subjective symptoms. The score ranges from 0 to 103 with a higher score indicating a more extensive and/or severe condition.

    Time frame: Week 0 to Week 16

  3. Change in Dermatology Life Quality Index (DLQI) Score From Baseline to Week 16

    DLQI is used by the participant to evaluate the impact of their condition on 10 different aspects of health-related quality of life (HRQoL) over the last week. Each item is scored on a 4-point Likert scale ranging from 0 (not at all/not relevant) to 3 (very much). The total score which is the sum of the 10 items ranges from 0 to 30, with a higher score indicating a poorer HRQoL.

    Time frame: Week 0 to Week 16

  4. Frequency of Anti-drug Antibodies (ADA)

    Presence of ADA from Week 0 to Week 32 was measured. Data were reported in the following categories: positive (presence of ADA at baseline and/or presence of ADA at at least 1 post-baseline assessment), perishing (presence of ADA at baseline and absence of ADA at all post-baseline assessments), negative (absence of ADA at all assessments), no post-baseline ADA assessment. Perishing ADAs were not assessed in the continuation treatment period.

    Time frame: Week 0 to Week 16, Week 16 to Week 32

  5. Amount of Topical Corticosteroid (TCS) Used Through Week 16 Assuming no TCS Used From the Non-returned Tubes

    Assessed as the amount of TCS weighed from previous visits, assuming no TCS was used from the non-returned tubes. Measurements were collected as TCS weight (g) between the visits.

    Time frame: Week 1-2 to Week 15-16

  6. Amount of Topical Corticosteroid (TCS) Used Through Week 16 Assuming All TCS Used From the Non-returned Tubes

    Assessed as the amount of TCS weighed from previous visits, assuming all TCS was used from the non-returned tubes. Measurements were collected as TCS weight (g) between the visits.

    Time frame: Week 1-2 to Week 15-16

  7. Number of Atopic Dermatitis Flares Through Week 16

    Assessed as appearance of new flares since previous visit.

    Time frame: Week 0 to Week 16

  8. Number of Days Without Topical Treatment Use From Baseline to Week 16

    Participants assessed their use of topical treatment over the past 24 hours using a response scale ('yes', 'no'). Measurements of number of days per week were used in the analysis.

    Time frame: Week 1 to Week 16

  9. Participants Achieving at Least 50% Reduction in Eczema Area and Severity Index (EASI) at Week 16

    EASI is used to evaluate the extent and severity of atopic dermatitis. It is a composite score ranging from 0 to 72 with a higher score indicating a more extensive and/or severe condition.

    Time frame: Week 16

  10. Participants Achieving at Least 90% Reduction in Eczema Area and Severity Index (EASI) at Week 16

    EASI is used to evaluate the extent and severity of atopic dermatitis. It is a composite score ranging from 0 to 72 with a higher score indicating a more extensive and/or severe condition.

    Time frame: Week 16

  11. Change From Baseline to Week 16 in Eczema Area and Severity Index (EASI) Score

    EASI is used to evaluate the extent and severity of atopic dermatitis. It is a composite score ranging from 0 to 72 with a higher score indicating a more extensive and/or severe condition.

    Time frame: Week 0 to Week 16

  12. Participants Achieving at Least 50% Reduction in Scoring Atopic Dermatitis (SCORAD) at Week 16

    SCORAD is used to evaluate the extent and severity of atopic dermatitis as well as subjective symptoms. The score ranges from 0 to 103 with a higher score indicating a more extensive and/or severe condition.

    Time frame: Week 16

  13. Participants Achieving at Least 75% Reduction in Scoring Atopic Dermatitis (SCORAD) at Week 16

    SCORAD is used to evaluate the extent and severity of atopic dermatitis as well as subjective symptoms. The score ranges from 0 to 103 with a higher score indicating a more extensive and/or severe condition.

    Time frame: Week 16

  14. Change From Baseline to Week 16 in Worst Daily Pruritus Numeric Rating Scale (NRS) (Weekly Average)

    Worst Daily Pruritus NRS is used by the participant to evaluate their worst itch severity over the past 24 hours. The score ranges from 0 ('no itch') to 10 ('worst itch imaginable') on an 11-point scale.

    Time frame: Week 0 to Week 16

  15. Reduction From Baseline to Week 16 of Dermatology Life Quality Index (DLQI) of at Least 4 Points Among Participants With Baseline DLQI ≥4

    DLQI is used by the participant to evaluate the impact of their condition on 10 different aspects of health-related quality of life (HRQoL) over the last week. Each item is scored on a 4-point Likert scale ranging from 0 (not at all/not relevant) to 3 (very much). The total score which is the sum of the 10 items ranges from 0 to 30, with a higher score indicating a poorer HRQoL.

    Time frame: Week 0 to Week 16

  16. Participants With Investigator's Global Assessment (IGA) Score of 0 (Clear) or 1 (Almost Clear) at Week 32 Among Participants With IGA Score of 0 or 1 at Week 16 After Initial Randomisation to Tralokinumab

    IGA is used to evaluate the severity of atopic dermatitis. It is a 5-point score ranging from 0 (clear) to 4 (severe).

    Time frame: Week 32

  17. Participants Achieving at Least 75% Reduction in Eczema Area and Severity Index (EASI) at Week 32 Among Participants Who Had Achieved at Least 75% Reduction in EASI at Week 16 After Initial Randomisation to Tralokinumab

    EASI is used to evaluate the extent and severity of atopic dermatitis. It is a composite score ranging from 0 to 72 with a higher score indicating a more extensive and/or severe condition.

    Time frame: Week 32

07

Results

Posted Jan 14, 2021

Participant flow

Initial Treatment Period
Participant flow — Initial Treatment Period
MilestoneTralokinumab Q2W+TCSPlacebo+TCSTralokinumab R/Q2W+TCSTralokinumab R/Q4W+TCSTralokinumab NR/Q2W+TCSPlacebo NR/Tralokinumab Q2W+TCSPlacebo R/Placebo+TCSSafety Follow-up
Started253127000000
Completed235120000000
Not completed187000000
Continuation Treatment Period
Participant flow — Continuation Treatment Period
MilestoneTralokinumab Q2W+TCSPlacebo+TCSTralokinumab R/Q2W+TCSTralokinumab R/Q4W+TCSTralokinumab NR/Q2W+TCSPlacebo NR/Tralokinumab Q2W+TCSPlacebo R/Placebo+TCSSafety Follow-up
Started0069699579410
Completed0068658772380
Not completed00148730
Safety Follow-up Period
Participant flow — Safety Follow-up Period
MilestoneTralokinumab Q2W+TCSPlacebo+TCSTralokinumab R/Q2W+TCSTralokinumab R/Q4W+TCSTralokinumab NR/Q2W+TCSPlacebo NR/Tralokinumab Q2W+TCSPlacebo R/Placebo+TCSSafety Follow-up
Started0000000278
Completed000000062
Not completed0000000216

Outcome measures

PrimaryParticipants With Investigator's Global Assessment (IGA) Score of 0 (Clear) or 1 (Almost Clear) at Week 16

IGA is used to evaluate the severity of atopic dermatitis. It is a 5-point score ranging from 0 (clear) to 4 (severe).

Time frame:
Week 16
Reported as:
Count of participants · Participants
Participants With Investigator's Global Assessment (IGA) Score of 0 (Clear) or 1 (Almost Clear) at Week 16
ParticipantsTralokinumab Q2W+TCSPlacebo+TCS
Participants With Investigator's Global Assessment (IGA) Score of 0 (Clear) or 1 (Almost Clear) at Week 169833
Statistical analysis
  • Tralokinumab Q2W+TCS vs Placebo+TCS · Cochran-Mantel-Haenszel · p = 0.015 (The primary endpoints were tested sequentially at a 5% significance level.) · Risk difference (rd): 12.4 · 95% CI 2.9 to 21.9The analysis was conducted using Cochran-Mantel-Haenszel test stratified by region and baseline disease severity.
PrimaryParticipants Achieving at Least 75% Reduction in Eczema Area and Severity Index (EASI) at Week 16

EASI is used to evaluate the extent and severity of atopic dermatitis. It is a composite score ranging from 0 to 72 with a higher score indicating a more extensive and/or severe condition.

Time frame:
Week 16
Reported as:
Count of participants · Participants
Participants Achieving at Least 75% Reduction in Eczema Area and Severity Index (EASI) at Week 16
ParticipantsTralokinumab Q2W+TCSPlacebo+TCS
Participants Achieving at Least 75% Reduction in Eczema Area and Severity Index (EASI) at Week 1614145
Statistical analysis
  • Tralokinumab Q2W+TCS vs Placebo+TCS · Cochran-Mantel-Haenszel · p = <0.001 (The primary endpoints were tested sequentially at a 5% significance level.) · Risk difference (rd): 20.2 · 95% CI 9.8 to 30.6The analysis was conducted using Cochran-Mantel-Haenszel test stratified by region and baseline disease severity.
SecondaryReduction of Worst Daily Pruritus Numeric Rating Scale (NRS) (Weekly Average) of at Least 4 From Baseline to Week 16

Worst Daily Pruritus NRS is used by the participant to evaluate their worst itch severity over the past 24 hours. The score ranges from 0 ('no itch') to 10 ('worst itch imaginable') on an 11-point scale.

Time frame:
Week 0 to Week 16
Reported as:
Count of participants · Participants
Reduction of Worst Daily Pruritus Numeric Rating Scale (NRS) (Weekly Average) of at Least 4 From Baseline to Week 16
ParticipantsTralokinumab Q2W+TCSPlacebo+TCS
Reduction of Worst Daily Pruritus Numeric Rating Scale (NRS) (Weekly Average) of at Least 4 From Baseline to Week 1611343
Statistical analysis
  • Tralokinumab Q2W+TCS vs Placebo+TCS · Cochran-Mantel-Haenszel · p = 0.037 (This secondary endpoint was tested after the sequential testing of the primary endpoints, if these showed statistical significance.) · Risk difference (rd): 11.3 · 95% CI 0.9 to 21.6The analysis was conducted using Cochran-Mantel-Haenszel test stratified by region and baseline disease severity.
SecondaryChange in Scoring Atopic Dermatitis (SCORAD) From Baseline to Week 16

SCORAD is used to evaluate the extent and severity of atopic dermatitis as well as subjective symptoms. The score ranges from 0 to 103 with a higher score indicating a more extensive and/or severe condition.

Time frame:
Week 0 to Week 16
Reported as:
Least squares mean · units on a scale
Change in Scoring Atopic Dermatitis (SCORAD) From Baseline to Week 16
units on a scaleTralokinumab Q2W+TCSPlacebo+TCS
Change in Scoring Atopic Dermatitis (SCORAD) From Baseline to Week 16-37.7 ± 1.25-26.8 ± 1.80
Statistical analysis
  • Tralokinumab Q2W+TCS vs Placebo+TCS · Repeated measurements model · p = <0.001 (This secondary endpoint was tested sequentially using the Holm method for multiplicity adjustment at a 5% significance level after the sequential testing of the primary endpoints and first secondary endpoint, if these showed statistical significance.) · Difference: -10.9 · 95% CI -15.2 to -6.6
SecondaryChange in Dermatology Life Quality Index (DLQI) Score From Baseline to Week 16

DLQI is used by the participant to evaluate the impact of their condition on 10 different aspects of health-related quality of life (HRQoL) over the last week. Each item is scored on a 4-point Likert scale ranging from 0 (not at all/not relevant) to 3 (very much). The total score which is the sum of the 10 items ranges from 0 to 30, with a higher score indicating a poorer HRQoL.

Time frame:
Week 0 to Week 16
Reported as:
Least squares mean · units on a scale
Change in Dermatology Life Quality Index (DLQI) Score From Baseline to Week 16
units on a scaleTralokinumab Q2W+TCSPlacebo+TCS
Change in Dermatology Life Quality Index (DLQI) Score From Baseline to Week 16-11.7 ± 0.39-8.8 ± 0.56
Statistical analysis
  • Tralokinumab Q2W+TCS vs Placebo+TCS · Repeated measurements model · p = <0.001 (This secondary endpoint was tested sequentially using the Holm method for multiplicity adjustment at a 5% significance level after sequential testing of the primary endpoints and the first secondary endpoint, if these showed statistical significance.) · Difference: -2.9 · 95% CI -4.3 to -1.6
SecondaryFrequency of Anti-drug Antibodies (ADA)

Presence of ADA from Week 0 to Week 32 was measured. Data were reported in the following categories: positive (presence of ADA at baseline and/or presence of ADA at at least 1 post-baseline assessment), perishing (presence of ADA at baseline and absence of ADA at all post-baseline assessments), negative (absence of ADA at all assessments), no post-baseline ADA assessment. Perishing ADAs were not assessed in the continuation treatment period.

Time frame:
Week 0 to Week 16, Week 16 to Week 32
Reported as:
Count of participants · Participants
Frequency of Anti-drug Antibodies (ADA)
ParticipantsInitial Treatment Period - Tralokinumab Q2W+TCSInitial Treatment Period - Placebo+TCSContinuation Treatment Period - Tralokinumab R/Q2W+TCSContinuation Treatment Period - Tralokinumab R/Q4W+TCSContinuation Treatment Period - Tralokinumab NR/Q2W+TCSContinuation Treatment Period - Placebo NR/Tralokinumab Q2W+TCSContinuation Treatment Period - Placebo R/Placebo+TCS
Initial treatment period (Week 0 to Week 16) — Positive2300000
Initial treatment period (Week 0 to Week 16) — Perishing1000000
Initial treatment period (Week 0 to Week 16) — Negative24612300000
Initial treatment period (Week 0 to Week 16) — No post-baseline ADA assessment3000000
Continuation treatment period (Week 16 to Week 32) — Positive0002032
Continuation treatment period (Week 16 to Week 32) — Perishing0000000
Continuation treatment period (Week 16 to Week 32) — Negative006663927437
Continuation treatment period (Week 16 to Week 32) — No post-baseline ADA assessment0000000
SecondaryAmount of Topical Corticosteroid (TCS) Used Through Week 16 Assuming no TCS Used From the Non-returned Tubes

Assessed as the amount of TCS weighed from previous visits, assuming no TCS was used from the non-returned tubes. Measurements were collected as TCS weight (g) between the visits.

Time frame:
Week 1-2 to Week 15-16
Reported as:
Least squares mean · g
Amount of Topical Corticosteroid (TCS) Used Through Week 16 Assuming no TCS Used From the Non-returned Tubes
gTralokinumab Q2W+TCSPlacebo+TCS
Week 1-229.3 ± 2.4532.8 ± 3.47
Week 3-419.7 ± 1.8626.6 ± 2.66
Week 5-618.5 ± 1.7223.2 ± 2.46
Week 7-817.0 ± 2.0424.3 ± 2.93
Week 9-1014.8 ± 1.6623.9 ± 2.38
Week 11-1211.6 ± 1.3819.6 ± 2.00
Week 13-1412.7 ± 1.6123.0 ± 2.33
Week 15-1611.6 ± 1.5720.2 ± 2.27
Statistical analysis
  • Tralokinumab Q2W+TCS vs Placebo+TCS · Repeated measurements model · p = 0.41 (The statistical test was not controlled for multiplicity.) · Difference: -3.5 · 95% CI -11.9 to 4.9
  • Tralokinumab Q2W+TCS vs Placebo+TCS · Repeated measurements model · p = 0.033 (The statistical test was not controlled for multiplicity.) · Difference: -6.9 · 95% CI -13.3 to -0.6
  • Tralokinumab Q2W+TCS vs Placebo+TCS · Repeated measurements model · p = 0.12 (The statistical test was not controlled for multiplicity.) · Difference: -4.7 · 95% CI -10.6 to 1.2
  • Tralokinumab Q2W+TCS vs Placebo+TCS · Repeated measurements model · p = 0.043 (The statistical test was not controlled for multiplicity.) · Difference: -7.3 · 95% CI -14.3 to -0.2
  • Tralokinumab Q2W+TCS vs Placebo+TCS · Repeated measurements model · p = 0.002 (The statistical test was not controlled for multiplicity.) · Difference: -9.1 · 95% CI -14.8 to -3.4
  • Tralokinumab Q2W+TCS vs Placebo+TCS · Repeated measurements model · p = 0.001 (The statistical test was not controlled for multiplicity.) · Difference: -8.0 · 95% CI -12.8 to -3.2
  • Tralokinumab Q2W+TCS vs Placebo+TCS · Repeated measurements model · p = <0.001 (The statistical test was not controlled for multiplicity.) · Difference: -10.2 · 95% CI -15.8 to -4.7
  • Tralokinumab Q2W+TCS vs Placebo+TCS · Repeated measurements model · p = 0.002 (The statistical test was not controlled for multiplicity.) · Difference: -8.6 · 95% CI -14.1 to -3.2
SecondaryAmount of Topical Corticosteroid (TCS) Used Through Week 16 Assuming All TCS Used From the Non-returned Tubes

Assessed as the amount of TCS weighed from previous visits, assuming all TCS was used from the non-returned tubes. Measurements were collected as TCS weight (g) between the visits.

Time frame:
Week 1-2 to Week 15-16
Reported as:
Least squares mean · g
Amount of Topical Corticosteroid (TCS) Used Through Week 16 Assuming All TCS Used From the Non-returned Tubes
gTralokinumab Q2W+TCSPlacebo+TCS
Week 1-240.1 ± 3.2240.1 ± 4.57
Week 3-432.4 ± 3.0031.3 ± 4.27
Week 5-629.2 ± 2.8930.6 ± 4.13
Week 7-825.2 ± 2.8930.0 ± 4.15
Week 9-1022.5 ± 2.6126.9 ± 3.76
Week 11-1216.9 ± 2.2323.1 ± 3.22
Week 13-1416.6 ± 2.2225.5 ± 3.23
Week 15-1615.3 ± 2.2624.8 ± 3.27
Statistical analysis
  • Tralokinumab Q2W+TCS vs Placebo+TCS · Repeated measurements model · p = 1.00 (The statistical test was not controlled for multiplicity.) · Difference: 0.0 · 95% CI -11.0 to 11.0
  • Tralokinumab Q2W+TCS vs Placebo+TCS · Repeated measurements model · p = 0.83 (The statistical test was not controlled for multiplicity.) · Difference: 1.1 · 95% CI -9.1 to 11.4
  • Tralokinumab Q2W+TCS vs Placebo+TCS · Repeated measurements model · p = 0.78 (The statistical test was not controlled for multiplicity.) · Difference: -1.4 · 95% CI -11.3 to 8.5
  • Tralokinumab Q2W+TCS vs Placebo+TCS · Repeated measurements model · p = 0.34 (The statistical test was not controlled for multiplicity.) · Difference: -4.8 · 95% CI -14.8 to 5.1
  • Tralokinumab Q2W+TCS vs Placebo+TCS · Repeated measurements model · p = 0.34 (The statistical test was not controlled for multiplicity.) · Difference: -4.4 · 95% CI -13.4 to 4.6
  • Tralokinumab Q2W+TCS vs Placebo+TCS · Repeated measurements model · p = 0.11 (The statistical test was not controlled for multiplicity.) · Difference: -6.2 · 95% CI -13.9 to 1.5
  • Tralokinumab Q2W+TCS vs Placebo+TCS · Repeated measurements model · p = 0.024 (The statistical test was not controlled for multiplicity.) · Difference: -8.9 · 95% CI -16.6 to -1.2
  • Tralokinumab Q2W+TCS vs Placebo+TCS · Repeated measurements model · p = 0.017 (The statistical test was not controlled for multiplicity.) · Difference: -9.5 · 95% CI -17.3 to -1.7
SecondaryNumber of Atopic Dermatitis Flares Through Week 16

Assessed as appearance of new flares since previous visit.

Time frame:
Week 0 to Week 16
Reported as:
Number · number of flares
Number of Atopic Dermatitis Flares Through Week 16
number of flaresTralokinumab Q2W+TCSPlacebo+TCS
Number of Atopic Dermatitis Flares Through Week 1611975
SecondaryNumber of Days Without Topical Treatment Use From Baseline to Week 16

Participants assessed their use of topical treatment over the past 24 hours using a response scale ('yes', 'no'). Measurements of number of days per week were used in the analysis.

Time frame:
Week 1 to Week 16
Reported as:
Least squares mean · days
Number of Days Without Topical Treatment Use From Baseline to Week 16
daysTralokinumab Q2W+TCSPlacebo+TCS
Week 12.6 ± 0.172.5 ± 0.25
Week 23.0 ± 0.182.6 ± 0.27
Week 32.9 ± 0.172.7 ± 0.25
Week 43.1 ± 0.172.7 ± 0.25
Week 53.2 ± 0.172.7 ± 0.25
Week 63.1 ± 0.182.8 ± 0.26
Week 73.3 ± 0.172.7 ± 0.25
Week 83.3 ± 0.183.0 ± 0.26
Week 93.6 ± 0.172.6 ± 0.25
Week 103.4 ± 0.172.7 ± 0.25
Week 113.6 ± 0.182.7 ± 0.26
Week 123.4 ± 0.182.7 ± 0.26
Week 133.5 ± 0.182.7 ± 0.26
Week 143.3 ± 0.182.6 ± 0.26
Week 153.5 ± 0.182.8 ± 0.26
Week 163.4 ± 0.193.0 ± 0.27
Statistical analysis
  • Tralokinumab Q2W+TCS vs Placebo+TCS · Repeated measurements model · p = 0.64 (The statistical test was not controlled for multiplicity.) · Difference: 0.1 · 95% CI -0.5 to 0.7
  • Tralokinumab Q2W+TCS vs Placebo+TCS · Repeated measurements model · p = 0.26 (The statistical test was not controlled for multiplicity.) · Difference: 0.4 · 95% CI -0.3 to 1.0
  • Tralokinumab Q2W+TCS vs Placebo+TCS · Repeated measurements model · p = 0.46 (The statistical test was not controlled for multiplicity.) · Difference: 0.2 · 95% CI -0.4 to 0.8
  • Tralokinumab Q2W+TCS vs Placebo+TCS · Repeated measurements model · p = 0.16 (The statistical test was not controlled for multiplicity.) · Difference: 0.4 · 95% CI -0.2 to 1.0
  • Tralokinumab Q2W+TCS vs Placebo+TCS · Repeated measurements model · p = 0.13 (The statistical test was not controlled for multiplicity.) · Difference: 0.5 · 95% CI -0.1 to 1.1
  • Tralokinumab Q2W+TCS vs Placebo+TCS · Repeated measurements model · p = 0.38 (The statistical test was not controlled for multiplicity.) · Difference: 0.3 · 95% CI -0.3 to 0.9
  • Tralokinumab Q2W+TCS vs Placebo+TCS · Repeated measurements model · p = 0.040 (The statistical test was not controlled for multiplicity.) · Difference: 0.6 · 95% CI 0.0 to 1.2
  • Tralokinumab Q2W+TCS vs Placebo+TCS · Repeated measurements model · p = 0.31 (The statistical test was not controlled for multiplicity.) · Difference: 0.3 · 95% CI -0.3 to 1.0
  • Tralokinumab Q2W+TCS vs Placebo+TCS · Repeated measurements model · p = 0.001 (The statistical test was not controlled for multiplicity.) · Difference: 1.0 · 95% CI 0.4 to 1.6
  • Tralokinumab Q2W+TCS vs Placebo+TCS · Repeated measurements model · p = 0.026 (The statistical test was not controlled for multiplicity.) · Difference: 0.7 · 95% CI 0.1 to 1.3
  • Tralokinumab Q2W+TCS vs Placebo+TCS · Repeated measurements model] · p = 0.006 (The statistical test was not controlled for multiplicity.) · Difference: 0.9 · 95% CI 0.2 to 1.5
  • Tralokinumab Q2W+TCS vs Placebo+TCS · Repeated measurements model · p = 0.043 (The statistical test was not controlled for multiplicity.) · Difference: 0.6 · 95% CI 0.0 to 1.3
  • Tralokinumab Q2W+TCS vs Placebo+TCS · Repeated measurements model · p = 0.010 (The statistical test was not controlled for multiplicity.) · Difference: 0.8 · 95% CI 0.2 to 1.4
  • Tralokinumab Q2W+TCS vs Placebo+TCS · Repeated measurements model · p = 0.037 (The statistical test was not controlled for multiplicity.) · Difference: 0.7 · 95% CI 0.0 to 1.3
  • Tralokinumab Q2W+TCS vs Placebo+TCS · Repeated measurements model · p = 0.045 (The statistical test was not controlled for multiplicity.) · Difference: 0.6 · 95% CI 0.0 to 1.3
  • Tralokinumab Q2W+TCS vs Placebo+TCS · Repeated measurements model · p = 0.17 (The statistical test was not controlled for multiplicity.) · Difference: 0.5 · 95% CI -0.2 to 1.1
SecondaryParticipants Achieving at Least 50% Reduction in Eczema Area and Severity Index (EASI) at Week 16

EASI is used to evaluate the extent and severity of atopic dermatitis. It is a composite score ranging from 0 to 72 with a higher score indicating a more extensive and/or severe condition.

Time frame:
Week 16
Reported as:
Count of participants · Participants
Participants Achieving at Least 50% Reduction in Eczema Area and Severity Index (EASI) at Week 16
ParticipantsTralokinumab Q2W+TCSPlacebo+TCS
Participants Achieving at Least 50% Reduction in Eczema Area and Severity Index (EASI) at Week 1620073
Statistical analysis
  • Tralokinumab Q2W+TCS vs Placebo+TCS · Cochran-Mantel-Haenszel · p = <0.001 (The statistical test was not controlled for multiplicity.) · Risk difference (rd): 21.3 · 95% CI 11.3 to 31.3The analysis was conducted using Cochran-Mantel-Haenszel test stratified by region and baseline disease severity.
SecondaryParticipants Achieving at Least 90% Reduction in Eczema Area and Severity Index (EASI) at Week 16

EASI is used to evaluate the extent and severity of atopic dermatitis. It is a composite score ranging from 0 to 72 with a higher score indicating a more extensive and/or severe condition.

Time frame:
Week 16
Reported as:
Count of participants · Participants
Participants Achieving at Least 90% Reduction in Eczema Area and Severity Index (EASI) at Week 16
ParticipantsTralokinumab Q2W+TCSPlacebo+TCS
Participants Achieving at Least 90% Reduction in Eczema Area and Severity Index (EASI) at Week 168327
Statistical analysis
  • Tralokinumab Q2W+TCS vs Placebo+TCS · Cochran-Mantel-Haenszel · p = 0.022 (The statistical test was not controlled for multiplicity.) · Risk difference (rd): 11.4 · 95% CI 2.1 to 20.7The analysis was conducted using Cochran-Mantel-Haenszel test stratified by region and baseline disease severity.
SecondaryChange From Baseline to Week 16 in Eczema Area and Severity Index (EASI) Score

EASI is used to evaluate the extent and severity of atopic dermatitis. It is a composite score ranging from 0 to 72 with a higher score indicating a more extensive and/or severe condition.

Time frame:
Week 0 to Week 16
Reported as:
Least squares mean · units on a scale
Change From Baseline to Week 16 in Eczema Area and Severity Index (EASI) Score
units on a scaleTralokinumab Q2W+TCSPlacebo+TCS
Change From Baseline to Week 16 in Eczema Area and Severity Index (EASI) Score-21.0 ± 0.67-15.6 ± 0.96
Statistical analysis
  • Tralokinumab Q2W+TCS vs Placebo+TCS · Repeated measurement model · p = <0.001 (The statistical test was not controlled for multiplicity.) · Difference: -5.4 · 95% CI -7.7 to -3.1
SecondaryParticipants Achieving at Least 50% Reduction in Scoring Atopic Dermatitis (SCORAD) at Week 16

SCORAD is used to evaluate the extent and severity of atopic dermatitis as well as subjective symptoms. The score ranges from 0 to 103 with a higher score indicating a more extensive and/or severe condition.

Time frame:
Week 16
Reported as:
Count of participants · Participants
Participants Achieving at Least 50% Reduction in Scoring Atopic Dermatitis (SCORAD) at Week 16
ParticipantsTralokinumab Q2W+TCSPlacebo+TCS
Participants Achieving at Least 50% Reduction in Scoring Atopic Dermatitis (SCORAD) at Week 1615448
Statistical analysis
  • Tralokinumab Q2W+TCS vs Placebo+TCS · Cochran-Mantel-Haenszel · p = <0.001 (The statistical test was not controlled for multiplicity.) · Risk difference (rd): 22.9 · 95% CI 12.4 to 33.3The analysis was conducted using Cochran-Mantel-Haenszel test stratified by region and baseline disease severity.
SecondaryParticipants Achieving at Least 75% Reduction in Scoring Atopic Dermatitis (SCORAD) at Week 16

SCORAD is used to evaluate the extent and severity of atopic dermatitis as well as subjective symptoms. The score ranges from 0 to 103 with a higher score indicating a more extensive and/or severe condition.

Time frame:
Week 16
Reported as:
Count of participants · Participants
Participants Achieving at Least 75% Reduction in Scoring Atopic Dermatitis (SCORAD) at Week 16
ParticipantsTralokinumab Q2W+TCSPlacebo+TCS
Participants Achieving at Least 75% Reduction in Scoring Atopic Dermatitis (SCORAD) at Week 166016
Statistical analysis
  • Tralokinumab Q2W+TCS vs Placebo+TCS · Cochran-Mantel-Haenszel · p = 0.012 (The statistical test was not controlled for multiplicity.) · Risk difference (rd): 11.1 · 95% CI 3.2 to 19.0The analysis was conducted using Cochran-Mantel-Haenszel test stratified by region and baseline disease severity.
SecondaryChange From Baseline to Week 16 in Worst Daily Pruritus Numeric Rating Scale (NRS) (Weekly Average)

Worst Daily Pruritus NRS is used by the participant to evaluate their worst itch severity over the past 24 hours. The score ranges from 0 ('no itch') to 10 ('worst itch imaginable') on an 11-point scale.

Time frame:
Week 0 to Week 16
Reported as:
Least squares mean · units on a scale
Change From Baseline to Week 16 in Worst Daily Pruritus Numeric Rating Scale (NRS) (Weekly Average)
units on a scaleTralokinumab Q2W+TCSPlacebo+TCS
Change From Baseline to Week 16 in Worst Daily Pruritus Numeric Rating Scale (NRS) (Weekly Average)-4.1 ± 0.15-2.9 ± 0.21
Statistical analysis
  • Tralokinumab Q2W+TCS vs Placebo+TCS · Repeated measurements model · p = <0.001 (The statistical test was not controlled for multiplicity.) · Difference: -1.2 · 95% CI -1.7 to -0.7
SecondaryReduction From Baseline to Week 16 of Dermatology Life Quality Index (DLQI) of at Least 4 Points Among Participants With Baseline DLQI ≥4

DLQI is used by the participant to evaluate the impact of their condition on 10 different aspects of health-related quality of life (HRQoL) over the last week. Each item is scored on a 4-point Likert scale ranging from 0 (not at all/not relevant) to 3 (very much). The total score which is the sum of the 10 items ranges from 0 to 30, with a higher score indicating a poorer HRQoL.

Time frame:
Week 0 to Week 16
Reported as:
Count of participants · Participants
Reduction From Baseline to Week 16 of Dermatology Life Quality Index (DLQI) of at Least 4 Points Among Participants With Baseline DLQI ≥4
ParticipantsTralokinumab Q2W+TCSPlacebo+TCS
Reduction From Baseline to Week 16 of Dermatology Life Quality Index (DLQI) of at Least 4 Points Among Participants With Baseline DLQI ≥420781
Statistical analysis
  • Tralokinumab Q2W+TCS vs Placebo+TCS · Cochran-Mantel-Haenszel · p = <0.001 (The statistical test was not controlled for multiplicity.) · Risk difference (rd): 17.6 · 95% CI 8.0 to 27.1The analysis was conducted using Cochran-Mantel-Haenszel test stratified by region and baseline disease severity.
SecondaryParticipants With Investigator's Global Assessment (IGA) Score of 0 (Clear) or 1 (Almost Clear) at Week 32 Among Participants With IGA Score of 0 or 1 at Week 16 After Initial Randomisation to Tralokinumab

IGA is used to evaluate the severity of atopic dermatitis. It is a 5-point score ranging from 0 (clear) to 4 (severe).

Time frame:
Week 32
Reported as:
Count of participants · Participants
Participants With Investigator's Global Assessment (IGA) Score of 0 (Clear) or 1 (Almost Clear) at Week 32 Among Participants With IGA Score of 0 or 1 at Week 16 After Initial Randomisation to Tralokinumab
ParticipantsTralokinumab R/Q2W+TCSTralokinumab R/Q4W+TCS
Participants With Investigator's Global Assessment (IGA) Score of 0 (Clear) or 1 (Almost Clear) at Week 32 Among Participants With IGA Score of 0 or 1 at Week 16 After Initial Randomisation to Tralokinumab4338
SecondaryParticipants Achieving at Least 75% Reduction in Eczema Area and Severity Index (EASI) at Week 32 Among Participants Who Had Achieved at Least 75% Reduction in EASI at Week 16 After Initial Randomisation to Tralokinumab

EASI is used to evaluate the extent and severity of atopic dermatitis. It is a composite score ranging from 0 to 72 with a higher score indicating a more extensive and/or severe condition.

Time frame:
Week 32
Reported as:
Count of participants · Participants
Participants Achieving at Least 75% Reduction in Eczema Area and Severity Index (EASI) at Week 32 Among Participants Who Had Achieved at Least 75% Reduction in EASI at Week 16 After Initial Randomisation to Tralokinumab
ParticipantsTralokinumab R/Q2W+TCSTralokinumab R/Q4W+TCS
Participants Achieving at Least 75% Reduction in Eczema Area and Severity Index (EASI) at Week 32 Among Participants Who Had Achieved at Least 75% Reduction in EASI at Week 16 After Initial Randomisation to Tralokinumab6259

Adverse events

Collected over Initial treatment period (Week 0 to Week 16), continuation treatment period (Week 16 to Week 32), safety follow-up (Week 32 to Week 46).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Initial Treatment Period: Tralokinumab Q2W+TCS0/252 (0%)2/252 (0.8%)118/252 (46.8%)
Initial Treatment Period: Placebo+TCS0/126 (0%)4/126 (3.2%)36/126 (28.6%)
Continuation Treatment Period: Tralokinumab R/Q2W+TCS0/69 (0%)3/69 (4.3%)30/69 (43.5%)
Continuation Treatment Period: Tralokinumab R/Q4W+TCS0/69 (0%)0/69 (0%)24/69 (34.8%)
Continuation Treatment Period: Tralokinumab NR/Q2W+TCS0/95 (0%)2/95 (2.1%)41/95 (43.2%)
Continuation Treatment Period: Placebo NR/Tralokinumab Q2W+TCS0/79 (0%)0/79 (0%)32/79 (40.5%)
Continuation Treatment Period: Placebo R/Placebo+TCS0/41 (0%)1/41 (2.4%)12/41 (29.3%)
Safety Follow-up0/278 (0%)3/278 (1.1%)10/278 (3.6%)
Most frequent serious events
Showing 10 of 16
Most frequent serious events
EventInitial Treatment Period: Tralokinumab Q2W+TCSInitial Treatment Period: Placebo+TCSContinuation Treatment Period: Tralokinumab R/Q2W+TCSContinuation Treatment Period: Tralokinumab R/Q4W+TCSContinuation Treatment Period: Tralokinumab NR/Q2W+TCSContinuation Treatment Period: Placebo NR/Tralokinumab Q2W+TCSContinuation Treatment Period: Placebo R/Placebo+TCSSafety Follow-up
Invasive ductal breast carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/2520/1260/690/690/950/791/410/278
AppendicitisInfections and infestations0/2520/1261/690/690/950/790/410/278
Gastroenteritis clostridialInfections and infestations0/2520/1261/690/690/950/790/410/278
Ligament ruptureInjury, poisoning and procedural complications0/2520/1261/690/690/950/790/410/278
HypoglycaemiaMetabolism and nutrition disorders0/2520/1261/690/690/950/790/410/278
Wrist fractureInjury, poisoning and procedural complications0/2520/1260/690/691/950/790/410/278
DepressionPsychiatric disorders0/2520/1260/690/691/950/790/410/278
Dermatitis infectedInfections and infestations0/2521/1260/690/690/950/790/410/278
Herpes zosterInfections and infestations0/2521/1260/690/690/950/790/410/278
Meningitis asepticInfections and infestations0/2521/1260/690/690/950/790/410/278
Most frequent other events
Most frequent other events
EventInitial Treatment Period: Tralokinumab Q2W+TCSInitial Treatment Period: Placebo+TCSContinuation Treatment Period: Tralokinumab R/Q2W+TCSContinuation Treatment Period: Tralokinumab R/Q4W+TCSContinuation Treatment Period: Tralokinumab NR/Q2W+TCSContinuation Treatment Period: Placebo NR/Tralokinumab Q2W+TCSContinuation Treatment Period: Placebo R/Placebo+TCSSafety Follow-up
Viral upper respiratory tract infectionInfections and infestations49/25214/12612/699/6920/9515/797/410/278
ConjunctivitisInfections and infestations28/2524/1264/690/693/953/791/410/278
Upper respiratory tract infectionInfections and infestations19/2526/1267/693/696/953/792/412/278
HeadacheNervous system disorders22/2526/1262/695/697/952/791/413/278
Dermatitis atopicSkin and subcutaneous tissue disorders6/25210/1261/691/698/956/792/412/278
Injection site reactionGeneral disorders17/2520/1265/694/695/952/790/410/278
DiarrhoeaGastrointestinal disorders8/2522/1264/691/691/952/792/411/278
NauseaGastrointestinal disorders0/2521/1263/694/693/951/790/412/278
Oral herpesInfections and infestations4/2521/1263/694/694/952/791/410/278

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Tralokinumab Q2W+TCSPlacebo+TCSTotal
<=18 years000
Between 18 and 65 years237119356
>=65 years16824
Age, Continuous
Age, Continuous(years)Tralokinumab Q2W+TCSPlacebo+TCSTotal
Mean39.8 ± 15.337.7 ± 14.839.1 ± 15.2
Sex: Female, Male
Sex: Female, Male(Participants)Tralokinumab Q2W+TCSPlacebo+TCSTotal
Female12843171
Male12584209
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Tralokinumab Q2W+TCSPlacebo+TCSTotal
Race — White20385288
Race — Black or African American231235
Race — Asian172441
Race — Native Hawaiian or Other Pacific Islander112
Race — Other9514
Race — Hispanic or Latino000
Race — Not Hispanic or Latino000
Ethnicity — White000
Ethnicity — Black or African American000
Ethnicity — Asian000
Ethnicity — Native Hawaiian or Other Pacific Islander000
Ethnicity — Other000
Ethnicity — Hispanic or Latino25934
Ethnicity — Not Hispanic or Latino228118346
Region of Enrollment
Region of Enrollment(Participants)Tralokinumab Q2W+TCSPlacebo+TCSTotal
Belgium15419
Canada342660
Germany421557
Netherlands9716
Poland481967
Spain121527
United Kingdom211334
United States7228100
Age at onset of atopic dermatitis
Age at onset of atopic dermatitis(years)Tralokinumab Q2W+TCSPlacebo+TCSTotal
Median4.0 (1.0 to 18.0)2.0 (1.0 to 12.0)4.0 (1.0 to 16.0)
Duration of atopic dermatitis
Duration of atopic dermatitis(years)Tralokinumab Q2W+TCSPlacebo+TCSTotal
Mean28.0 ± 16.528.7 ± 15.028.2 ± 16.0
Body surface area with atopic dermatitis
Body surface area with atopic dermatitis(percentage affected)Tralokinumab Q2W+TCSPlacebo+TCSTotal
Mean47.6 ± 23.349.0 ± 25.948.1 ± 24.2

5 further baseline measures are reported on the registry.

08

Study locations

66 sites
  • University of Alabama-Birmingham
    Birmingham, Alabama 35233, United States
  • California Dermatology & Clinical Research Institute
    Encinitas, California 92024, United States
  • First OC Dermatology
    Fountain Valley, California 92708, United States
  • Center for Dermatology Clinical Research
    Fremont, California 94538, United States
  • Dermatology Research Associates
    Los Angeles, California 90045, United States
  • Clinical Science Institute
    Santa Monica, California 90404, United States
  • Danbury Clinical Research
    Danbury, Connecticut 06810, United States
  • International Dermatology Research
    Miami, Florida 33144, United States
  • L & C Professional Medical Research
    Miami, Florida 33144, United States
  • Lenus Research & Medical Group
    Sweetwater, Florida 33172, United States
  • Olympian Clinical Research
    Tampa, Florida 33614, United States
  • Medical Dermatology Specialists
    Atlanta, Georgia 30328, United States
  • Northwestern University
    Chicago, Illinois 60611, United States
  • Indiana Clinical Trials Center
    Plainfield, Indiana 46168, United States
  • Study Center
    Bangor, Maine 04401, United States
  • Respiratory Medicine Research
    Ypsilanti, Michigan 48197, United States
  • Mount Sinai West Dermatoogy
    New York, New York 10023, United States
  • Wake Research
    Raleigh, North Carolina 27612, United States
  • Dermatologists of Greater Columbus
    Bexley, Ohio 43209, United States
  • Oregon Dermatology & Research
    Portland, Oregon 97210, United States
  • National Allergy and Asthma Research, LLC
    North Charleston, South Carolina 29420, United States
  • University Hospital Antwerp
    Antwerp, 2650, Belgium
  • Universitair ziekenhuis Brussel
    Brussels, 1090, Belgium
  • Cliniques Universitaires St-Luc
    Brussels, 1200, Belgium
  • LEO Pharma Investigational Site
    Loverval, 6280, Belgium
  • Institute for Skin Advancement
    Calgary, Alberta T3A 2N1, Canada
  • Skin Care Centre
    Vancouver, British Columbia V5Z 4E8, Canada
  • Maritime Medical Research Centre
    Bathurst, New Brunswick E2A 4Z9, Canada
  • Eastern Canada Cutaneous Research
    Halifax, Nova Scotia B3H 1Z4, Canada
  • CCA Medical Research
    Ajax, Ontario L1S 7K8, Canada
  • Simcoderm Medical and Surgical Dermatology Centre
    Barrie, Ontario L4M 6L2, Canada
  • DermEdge Research
    Mississauga, Ontario L5H 1G9, Canada
  • York Dermatology Center
    Richmond Hill, Ontario L4C 9M7, Canada
  • Research Toronto
    Toronto, Ontario M4W 2N2, Canada
  • XLR8 Medical Research
    Windsor, Ontario N8W 1E6, Canada
  • Interdisciplinary Study Association GmbH
    Berlin, 10780, Germany
  • St. Josef-Hospital, Ruhr-Universitet
    Bochum, 44791, Germany
  • Klinik und Poliklinik für Dermatologie und Allergologie
    Bonn, 53105, Germany
  • Klinikum der Johann Wolfgang Goethe-Universität Klinik
    Frankfurt am Main, 60590, Germany
  • MensingDerma Research GmbH
    Hamburg, 22391, Germany
  • Universitätsklinikum Jena
    Jena, 07743, Germany
  • Universitätshautklinik Kiel
    Kiel, 24105, Germany
  • Universitätsklinikum Tübingen
    Tuebingen, 72076, Germany
  • Amcademic Medical Center
    Amsterdam, 1105 AZ, Netherlands
  • LEO Pharma Investigational Site
    Bergen Op Zoom, 4614 VT, Netherlands
  • LEO Pharma Investigational Site
    Groningen, 9713 GZ, Netherlands
  • Radboud MC
    Nijmegen, 6525, Netherlands
  • Erasmus MC, Rotterdam
    Rotterdam, 3015 CA, Netherlands
  • University Medical Centre Utrecht
    Utrecht, 3584 CX, Netherlands
  • Nzoz Med-Laser
    Lublin, 20-146, Poland
  • LEO Pharma Investigational Site
    Rzeszów, 35-055, Poland
  • Wojskowy Instytut Medyczny
    Warszawa, 01-0141, Poland
  • Wromedica s.c.
    Wroclaw, 50-001, Poland
  • Derm Medica Sp.zo.o.
    Wrocław, 51-318, Poland
  • Hospital General de Alicante
    Alicante, 03010, Spain
  • Hospital Universitari de Bellvitge
    Barcelona, 08907, Spain
  • Fundación Hospital Alcorcón
    Madrid, 28922, Spain
  • Hospital de Pontevedra
    Pontevedra, 36003, Spain
  • Hospital General de Valencia
    Valencia, 46014, Spain
  • Addenbooke's Hospital
    Cambridge, Cambridgeshire CB2 0QQ, United Kingdom
  • The Princess Alexandra Hospital
    Harlow, Essex CM20 1QX, United Kingdom
  • East Surrey Hospital
    Redhill, Surrey RH1 5RH, United Kingdom
  • Queen Elizabeth Hospital Birmingham
    Birmingham, West Midlands B15 2TH, United Kingdom
  • Russells Hall Hospital
    Dudley, West Midlands DY1 2HQ, United Kingdom
  • The Royal Free Hospital
    London, NW3 2QG, United Kingdom
  • Guy's and St Thomas' NHS Foundation Trust
    London, SE1 9RT, United Kingdom
09

References and documents

Publications

  • Blauvelt A, Gooderham M, Bhatia N, Langley RG, Schneider S, Zoidis J, Kurbasic A, Armstrong A, Silverberg JI. Tralokinumab Efficacy and Safety, with or without Topical Corticosteroids, in North American Adults with Moderate-to-Severe Atopic Dermatitis: A Subanalysis of Phase 3 Trials ECZTRA 1, 2, and 3. Dermatol Ther (Heidelb). 2022 Nov;12(11):2499-2516. doi: 10.1007/s13555-022-00805-y. Epub 2022 Sep 24. PubMed 36152216 ↗
  • Simpson EL, Merola JF, Silverberg JI, Reich K, Warren RB, Staumont-Salle D, Girolomoni G, Papp K, de Bruin-Weller M, Thyssen JP, Zachariae R, Olsen CK, Wollenberg A. Safety of tralokinumab in adult patients with moderate-to-severe atopic dermatitis: pooled analysis of five randomized, double-blind, placebo-controlled phase II and phase III trials. Br J Dermatol. 2022 Dec;187(6):888-899. doi: 10.1111/bjd.21867. Epub 2022 Oct 26. PubMed 36082590 ↗
  • Silverberg JI, Adam DN, Zirwas M, Kalia S, Gutermuth J, Pinter A, Pink AE, Chiricozzi A, Barbarot S, Mark T, Tindberg AM, Weidinger S. Tralokinumab Plus Topical Corticosteroids as Needed Provides Progressive and Sustained Efficacy in Adults with Moderate-to-Severe Atopic Dermatitis Over a 32-Week Period: An ECZTRA 3 Post Hoc Analysis. Am J Clin Dermatol. 2022 Jul;23(4):547-559. doi: 10.1007/s40257-022-00702-2. Epub 2022 Jul 20. PubMed 35857179 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2018 to primary completion in Mar 2019, 12 months.

Results were first posted in Jan 2021, 1 year 10 months after primary completion. A results delay was requested in Oct 2019.

Of 150 industry-sponsored phase 3 interventional studies under Dermatitis, Atopic, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 28. This study's 12 months is below that.

Counting every sponsor, half of 157 studies reached it within 18 months; a quarter within 13 and three quarters within 28.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 1, 2017
First posted
Dec 6, 2017
StartActual
Feb 22, 2018
Primary completionActual
Mar 8, 2019
CompletionActual
Sep 26, 2019
Results delay requested
Oct 15, 2019
Results first posted
Jan 14, 2021
Last update
Mar 11, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 11, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03363854
Lead sponsor
LEO Pharma
Responsible party
Sponsor
First posted
Dec 6, 2017
Start date
Feb 22, 2018
Primary completion
Mar 8, 2019
Completion
Sep 26, 2019
Results posted
Jan 14, 2021
Last update
Mar 11, 2025

Study contacts

Medical expert
study director · LEO Pharma

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tralokinumab

Start the discussion